IP Library › Granted Patent US 9,480,713
Granted Patent B2
US 9,480,713 · App. 14/535,827 · Granted Nov 1, 2016

Method for treating diabetic renal failure or syndrome X

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,480,713
App. No.
14/535,827
Granted
Nov 1, 2016
Kind
B2
Abstract

The present invention provides a method for improving pancreatic function in a subject in need thereof, the method comprising administering to the subject STRO-1 + cells and/or progeny cells thereof and/or soluble factors derived therefrom. The method of the invention is useful for treating and/or preventing and/or delaying the onset or progression of a disorder resulting from or associated with pancreatic dysfunction, e.g., resulting from abnormal endocrine or exocrine function of the pancreas.

Claims (8)

1. A method for treating diabetic renal failure or syndrome X in a subject in need thereof, the method comprising administering to the subject STRO-1 + cells and/or progeny cells thereof and/or soluble factors derived therefrom.

2. The method of claim 1 , wherein the STRO-1 + cells and/or progeny cells thereof and/or soluble factors derived therefrom are administered directly into the bloodstream of a subject.

3. The method of claim 2 , wherein the STRO-1 + cells and/or progeny cells thereof and/or soluble factors derived therefrom are administered intra-arterially.

4. The method of claim 1 , wherein the STRO-1 + cells administered to the subject are STRO-1 bri , and/or express tissue non-specific alkaline phosphatase (TNAP) and/or the progeny cells and/or soluble factors are derived from STRO-1 + cells that are STRO-1 bri and/or express TNAP.

5. The method of claim 1 for treating or delaying the progression of diabetic renal failure or syndrome X, wherein the STRO-1 + cells and/or progeny cells thereof and/or soluble factors derived therefrom are administered following diagnosis of the diabetic renal failure or syndrome X.

6. The method of claim 1 additionally comprising monitoring or detecting onset and/or progression of diabetic renal failure or syndrome X.

7. The method of claim 1 , wherein the STRO-1 + cells and/or progeny cells thereof and/or soluble factors derived therefrom are administered in the form of a composition comprising said STRO-1 + cells and/or progeny cells thereof and/or soluble factors derived therefrom and a carrier and/or excipient.

8. The method of claim 1 , wherein the STRO-1 + cells are culture expanded prior to administration to the subject.

Assignments (6)
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jan 2, 2026
From: OAKTREE FUND ADMINISTRATION, LLC, AS AGENT
To: MESOBLAST LIMITED; MESOBLAST UK LIMITED; MESOBLAST, INC. (FORMERLY KNOWN AS ANGIOBLAST, INC.); MESOBLAST INTERNATIONAL SÀRL
Reel/Frame 074174/0183 →
RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT AT REEL/FRAME NO. 45759/0682 Recorded Jul 30, 2025
From: HERCULES CAPITAL, INC., AS AGENT
To: MESOBLAST, INC.
Reel/Frame 072294/0555 →
SECURITY INTEREST Recorded Dec 10, 2021
From: MESOBLAST LIMITED ACN 109 431 870; MESOBLAST UK LIMITED; MESOBLAST, INC. (FORMERLY KNOWN AS ANGIOBLAST, INC.); MESOBLAST INTERNATIONAL SÀRL
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 058957/0447 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Mar 28, 2018
From: MESOBLAST, INC.
To: HERCULES CAPITAL, INC., AS ADMINISTRATIVE AND COLLATERAL AGENT
Reel/Frame 045759/0682 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2017
From: ITESCU, SILVIU; KRISHNAN, RAVI
To: ANGIOBLAST SYSTEMS, INC.
Reel/Frame 044451/0858 →
CHANGE OF NAME Recorded Dec 20, 2017
From: ANGIOBLAST SYSTEMS, INC.
To: MESOBLAST, INC.
Reel/Frame 044956/0868 →